EyePoint (EYPT) expects its cash, cash equivalents, and marketable securities as of September 30, 2025, along with the net proceeds from the October equity financing, will enable the Company to fund operations into the fourth quarter of 2027.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- EyePoint price target raised to $33 from $28 at Mizuho
- EyePoint Pharma’s DEXYCU Study: A Potential Game-Changer in Pediatric Cataract Treatment
- EYPT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- EyePoint Pharmaceuticals Raises $141M in Public Offering
- EyePoint reports inducement grants under NASDAQ listing rule